Skip to main content
Springer logoLink to Springer
. 2020 Mar 20;22(4):992. doi: 10.1007/s11307-020-01493-w

Correction to: Preclinical Evaluation and Dosimetry of [111In] CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1)

Francesco Cicone 1,2,, Thibaut Denoël 1, Silvano Gnesin 3, Nicolo Riggi 4, Melita Irving 5, Gopinadh Jakka 5, Niklaus Schaefer 1, David Viertl 1, George Coukos 5, John O Prior 1
PMCID: PMC7645449  PMID: 32198704

Correction to: Mol Imaging Biol.

10.1007/s11307-020-01479-8

In the original article, some numerical values in the following paragraph were reported incorrectly:

“In fact, the direct method would give absorbed doses 5.6 (0.927 vs. 0.165 mGy/MBq) and 13.2 (1.88 vs. 0.142 mGy/MBq) times higher for uterus and ovaries, respectively, compared with the method we adopted. Smaller, but still relevant, overestimations of 65 and 95 % would be obtained with the direct method for other important organs, such as the liver (0.921 vs. 0.570 mGy/MBq) and the kidneys (0.580 vs. 0.298 mGy/MBq), respectively (full data not shown)”.

The paragraph has been updated to read:

“In fact, the direct method would give absorbed doses 5.5 (0.907 vs. 0.165 mGy/MBq) and 5.2 (0.731 vs. 0.142 mGy/MBq) times higher for uterus and ovaries, respectively, compared with the method we adopted. Smaller, but still relevant, overestimations of 62 and 94 % would be obtained with the direct method for other important organs, such as the liver (0.923 vs. 0.570 mGy/MBq) and the kidneys (0.577 vs. 0.298 mGy/MBq), respectively (full data not shown)”.

Footnotes

The online version of the original article can be found at 10.1007/s11307-020-01479-8


Articles from Molecular Imaging and Biology are provided here courtesy of Springer

RESOURCES